Nexalin Technology (NXL) Income from Continuing Operations (2021 - 2026)
Nexalin Technology (NXL) recorded quarterly Income from Continuing Operations of 2096837.0 in Q1 2026, up 11.77% quarter-over-quarter from 2376546.0 in Q4 2025, and down 5.51% on a YoY basis from 2219167.13 in Q1 2025.
Nexalin Technology (NXL) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Nexalin Technology's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 2096837.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 5.51% year-over-year to 2096837.0; the TTM figure through Mar 2026 stood at 8330681.0 (up 2.59% YoY), while the FY2025 annual figure was 8221133.0, down 8.0% from the prior year.
- Income from Continuing Operations was 2096837.0 for Q1 2026 at Nexalin Technology, up from 2376546.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 303646.0 in Q3 2022 to a low of 2833475.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 1438460.18 across 5 years, with a median of 1283202.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations jumped 83.34% in 2022, then slumped 656.54% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 733113.0 in 2022, then retreated by 6.49% to 780669.0 in 2023, then sank by 262.95% to 2833475.0 in 2024, then rose by 16.13% to 2376546.0 in 2025, then climbed by 11.77% to 2096837.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2096837.0 (Q1 2026), 2376546.0 (Q4 2025), and 2276311.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 380.70 Mn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 273.95 Mn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 199.50 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 220.30 Mn |
| 10 | Nexalin Technology | 8.72 Mn | 6.01 Mn | 13,133.00 | -2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.10 Mn |
| Dec 31, 2025 | -2.38 Mn |
| Sep 30, 2025 | -2.28 Mn |
| Jun 30, 2025 | -1.58 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | -2.83 Mn |
| Sep 30, 2024 | -2.45 Mn |
| Jun 30, 2024 | -1.28 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -780,669.00 |
| Sep 30, 2023 | -2.30 Mn |
| Jun 30, 2023 | -822,437.00 |
| Mar 31, 2023 | -748,414.00 |
| Dec 31, 2022 | -733,113.00 |
| Sep 30, 2022 | -303,646.00 |
| Jun 30, 2022 | -445,103.00 |
| Mar 31, 2022 | -393,249.00 |
| Dec 31, 2021 | -595,928.00 |
| Sep 30, 2021 | -1.82 Mn |